
July 14 (Reuters) - AstraZeneca PLC AZN.L:
BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL
ASTRAZENECA PLC - BAXDROSTAT MEETS PRIMARY AND SECONDARY ENDPOINTS IN PHASE III TRIAL
ASTRAZENECA PLC - BAXDROSTAT SHOWS SIGNIFICANT REDUCTION IN SYSTOLIC BLOOD PRESSURE
ASTRAZENECA PLC - BAXDROSTAT AT 2MG AND 1MG DOSES REDUCES BLOOD PRESSURE
ASTRAZENECA: BAXDROSTAT WAS GENERALLY WELL TOLERATED WITH A FAVOURABLE SAFETY PROFILE